Abiopharma

Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

4DMT Provides Company Update and Anticipated Development Milestones for 2026

Alterity Therapeutics Limited (ATHE) Files Form 6-K

Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

BrainsWay Announces First Coverage Policy for Accelerated Deep TMS™

BRAINSWAY (BWAY) Files Form 6-K

Sotera Health to Present at the 44th Annual J.P. Morgan Healthcare Conference

FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum

TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy

GSK plc (GLAXF) Files Form 6-K

(90% Positive) MONTE ROSA THERAPEUTICS, INC. (GLUE) Provides Update on development for today at 8 a